Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1183/09031936.00114311 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Evaluation of the efficacy of antifibrotic drugs on cell cultures in Salzmann's nodular degeneration].
Vestn Oftalmol
December 2024
Krasnov Research Institute of Eye Diseases, Moscow, Russia.
Unlabelled: Excessive production of extracellular matrix is a key component in the pathogenesis of Salzmann's nodular degeneration (SND). studies of drugs that suppress excessive fibroblast activity may become crucial in developing pathogenetically oriented treatments for SND.
Purpose: This study evaluates the antifibrotic properties of pirfenidone and cyclosporine A (CsA) on cell cultures obtained from patients with SND.
Personalized Antifibrotic Therapy in CKD Progression.
J Pers Med
December 2024
Department of Nephrology, Ghent University Hospital, 9000 Ghent, Belgium.
Chronic kidney disease (CKD) is a chronic disorder characterized by kidney fibrosis and extracellular matrix accumulation that can lead to end-stage kidney disease. Epithelial-to-mesenchymal transition, inflammatory cytokines, the TGF-β pathway, Wnt/β-catenin signaling, the Notch pathway, and the NF-κB pathway all play crucial roles in the progression of fibrosis. Current medications, such as renin-angiotensin-aldosterone system inhibitors, try to delay disease development but do not stop or reverse fibrosis.
View Article and Find Full Text PDFTreatable traits in idiopathic pulmonary fibrosis: focus on respiratory tract infections-a systematic review and a meta-analysis.
EClinicalMedicine
January 2025
Department of Pulmonology, Semmelweis University, Budapest, Hungary.
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive, deadly lung disease with several factors, including respiratory tract infections (RTI), for disease worsening. There's no comprehensive data on RTI incidence in IPF patients across different therapies, including antifibrotic (nintedanib or pirfenidone), investigative or placebo treatments.
Methods: A systematic search of databases Medline, EMBASE, Cochrane Central, Web of Science and Scopus was conducted on September 30th 2024 (PROSPERO registration number: CRD42023484213).
Effect of Transforming Growth Factor-β Inhibition on Ureteral and Renal Scarring in a Rat Model of Upper Urinary Tract Ablation with Irreversible Electroporation.
Bioelectricity
December 2024
Department of Mechanical and Industrial Engineering, University of Massachusetts Amherst, Amherst, Massachusetts, USA.
Objective: To determine whether adjuvant transforming growth factor-β (TGF-β) inhibition with pirfenidone (PFD) can mitigate ureteral wall scarring and related complications in a rat model of upper urinary tract ablation with irreversible electroporation (IRE).
Methods: Transmural ablation of the ureter was performed with IRE in 24 rats. Post-IRE, animals were randomly assigned to receive PFD or no drug, followed by euthanasia at 2-, 5-, or 10-days.
Computed tomography morphomics and antifibrotic therapy in idiopathic pulmonary fibrosis.
Clin Radiol
November 2024
School of Medicine, Cork University Hospital, Cork, Ireland; Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland.
Aim: Idiopathic pulmonary fibrosis (IPF) is a debilitating and fatal lung disease. Changes in body composition potentially correlate with outcomes in patients with IPF.
Materials And Methods: Patients with IPF on antifibrotic treatment attending a single institution were identified and retrospectively evaluated (n=84).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!